XML 77 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Sep. 30, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Aug. 02, 2022
Jan. 05, 2021
Finite-Lived Intangible Assets [Line Items]                
Cost       $ 1,007,331,000 $ 981,016,000      
Finite-lived intangible assets, accumulated amortization       366,935,000 274,776,000      
Finite-lived Intangible assets, net       640,396,000 706,240,000      
Goodwill, impairment loss       0 0 $ 0    
Thrive                
Finite-Lived Intangible Assets [Line Items]                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets               $ 1,250,000,000
Oncotype DX Genomic Prostate Score Test | Disposal Group, Disposed of by Sale, Not Discontinued Operations                
Finite-Lived Intangible Assets [Line Items]                
Cost             $ 59,000,000  
Finite-lived intangible assets, accumulated amortization             16,100,000  
Finite-lived Intangible assets, net             $ 42,900,000  
In-process research and development                
Finite-Lived Intangible Assets [Line Items]                
Impairment of long-lived assets     $ 20,200,000          
Service Agreements [Member]                
Finite-Lived Intangible Assets [Line Items]                
Impairment of long-lived assets $ 2,000,000              
Developed Technology Rights [Member]                
Finite-Lived Intangible Assets [Line Items]                
Cost       887,789,000 861,474,000      
Finite-lived intangible assets, accumulated amortization       328,543,000 245,527,000      
Finite-lived Intangible assets, net       $ 559,246,000 $ 615,947,000      
Impairment of long-lived assets   $ 6,600,000